International Journal for Research in Applied Sciences and Biotechnology

ISSN: 2349-8889
Volume-9, Issue-1 (January 2022)

www.ijrasb.com

https://doi.org/10.31033/ijrasb.9.1.9

Article Review: Autosomal Dominant Polycystic Kidney Disease: Renal Physiology Diagnosis, Treatment and Novel Therapies

Rana Hazim Hamoode[1], Dalal A. Sattar[2] and Mohanad A. K.[3]
[1]Department of Basic Sciences, College of Dentistry, University of Anbar, Al-Anbar, IRAQ.
[2]Department of Biology, College of Science, Mustansiriyah University, Baghdad, IRAQ.
[3]Department of Biology, College of Science, Mustansiriyah University, Baghdad, IRAQ.

[1]Corresponding Author: den.rana.hazm@uoanbar.edu.iq

ABSTRACT

In the case of Autosomal dominant polycystic kidney disease, patients are usually cured with Vasopressin (V2) receptor antagonists, which delay the ongoing growth of cyst formation and slow the pace of AD disease progression. Before we know more, it is uncertain if the increase in vasopressin amide levels that was detected during V2RAT treatment impacts the production of glucose in the intestines. Cell growth and fluid secretion are aided by high intracellular concentrations of adenosine 3',5;-cyclic monophosphate (cAMP), which leads to cyst development. SST, a hormone implicated in a variety of cell activities, has the potential to block the generation of intracellular cAMP. Nevertheless, since Somatostatin is quickly removed in vivo, it has little therapeutic promise. As a result, analogues with a longer half-life have been established, which might be potential medicines in the therapy of ADPKD. This review covers the complicated physiological consequences of Somatostatin, especially on the kidneys, as well as the possible therapeutic use of SST analogues in ADPKD.

Keywords- Kidney Disease, Renal Physiology, Somatostatin, IgA nephropathy.

I. INTRODUCTION

Adoption of the prevalent “polycystic kidney disease (AD-PKD)” is an hereditary ailment where the kidneys develop multiple cysts, causing kidney activity to be significantly reduced. A growing number of people diagnosed with Aortic incompetence are treated with vaptoglucerpine V2 antagonist vasopressin V2 antagonism, which can delay their disease development. The V2 receptor associates with and activates the aquin II (specifically, channel-translocating) channels in the renal tubule epithelial cells, which causes movement of the cells to the cells to the accumulating tubule membrane[1]. These channels enable water to pass from the lumen into the interstitial tissue and into the surrounding capillary capillaries, which lessens urinary production. To inhibit the V2 vasopressin receptor activity, a vasopressin V2 antagonist elicits an increase in vasopressin's urinary osmol and plasma accumulation, resulting in an increase in vasin secretion from the neurosecretory glands. Polyamide is a strong-ampiaz that does not selectively antagonize vasopressin and may be antagonised by other vasodilators other than this one. Since vasopressin stimulates each of these subtypes, exposure to high levels of the medication can drive the vasopressorsiont level higher. Before then, the answer to this question is discovered; it is uncertain whether this would have any therapeutic effect.

Vasopressin can also bind to “V1 and V3 receptors on the adrenal cortex”, and then causes a direct rise in cortisol secretion. Researchers are exploring the HPA axis in ADPKD patients to provide fresh information on the interrelationship between cortisol synthesis and antidiuretic hormone. For medicinal purposes, an improvement in glucose-related derivatives might be important[4]. Because a small increase in cortisol levels increases coronary incidents and mortality, researchers believe that stress levels may be especially important in individuals in this case. The present term the need for further vigilance in the study of ADPKD patients concerning cardiovascular complications resulting from the tendency of their disease to expand.

We wanted to explore first, then, therefore, how stable individuals and patients with IgA nephropathy-induced ADPKD (impaired kidney glomerulide associated nephropathy) compare with healthy controls on their HPA axis baseline behaviour. This community was then studied as well to discover if improvements in glucoside excretion[5] were only related to the decline in kidney function or if they may be due to other factors that could also affect their functioning.[6] To see the impact of the rise in vasopressin levels on glucocoid metabolism, the experiment was conducted in the presence of V2 receptor antagonist.

SST is a hormone that suppresses cAMP generation in a change of organs, and the liver and kidney, both direct and indirect. Somatostatin analogues may thus have a function in the therapy of both the renal and hepatic phenotypes of ADPKD. The majority of research on Somatostatin as well as its complicated “signalling pathway is from the 1980s and 1990s”. The function of Somatostatin and Somatostatin analogues in physiology, with an emphasis on renal consequences, especially in the pathophysiology of ADPKD, is summarised in this study. Somatostatin's hepatic impacts have lately been evaluated in another publication.

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN: 2349-8889
Volume-9, Issue-1 (January 2022)

www.ijrasb.com https://doi.org/10.31033/ijrasb.9.1.9

II. PAST OF SOMATOSTATIN

Krulich identified SST or SRIF as a development hormone substance generated by the hypothalamus in the year 1968. “Hellman and Lernmark discovered an insulin-inhibiting factor secreted by the pancreas a year later”. Brazeau determined in 1973 that the same hormone, somatostatin, was responsible for both events. Following its finding, investigations indicated that somatostatin is generated more broadly all through body and also has a wide range of biological actions, the majority of which are inhibitory.

The physiology of SST:

SST is produced as part of preprosomatostatin (prepro Somatostatin), a big “precursor protein” that is swiftly converted into “prosomatostatin” (pro Somatostatin). The C-terminal portion of this prohormone is enzymatically digested to produce two bioactive forms, Somatostatin -14 and Somatostatin -28. Pro Somatostatin may also be cleaved at some other locations, resulting in four additional cleavage goods, however it's unclear if these later cleavage products have any physiological role.



Figure 1: SST: its precursors and cleavage products (modified from Patel et al. [13]).

Secretion of Somatostatin:

Somatostatin is made by a variety of cell types. The majority of Somatostatin-producing cells may be located in the central as well as peripheral neurological systems, and also the pancreas and also the “gastrointestinal tract”. Somatostatin-producing cells may also be detected in other organs, but in lesser quantities, such as the kidney. The gastrointestinal tract accounts for around 65 percent of total body Somatostatin, whereas the central nervous system accounts for 25%, the pancreas for 5%, and the other organs for 5%. A wide range of substances, including ions, minerals, neurotransmitters, peptides, growth factors, hormones, including cytokines, may either promote or inhibit SST secretion. Some of these drugs have similar impacts on SST cells in various parts of the body, while others seem to have tissue-specific impacts. For instance, foods such as glucose enhance Somatostatin secretion by pancreatic d-cells while inhibiting Somatostatin secretion by hypothalamic cells.

Renal localization of Somatostatin-producing cells as well as STRs:

Somatostatin-producing cells may also be detected in the kidney, as previously stated. Somatostatin is released by mesangial cells including proximal tubular cells, according to in vitro research. cAMP stimulates secretion, whereas epidermal development element and hydrocortisone suppress it. Because Somatostatin is an intrinsic inhibitory regulator, it's possible that even after attaching to renal SomatostatinRs, this renalderived Somatostatin controls mesangial and proximal tubular cell development and function. Only a few research have looked at the location of SSTRs in the kidney. Somatostatin R1, -2, and -5 are mostly found in the distal tubules, according to this research. Conversely, with the exception of the collecting duct, a recent investigation demonstrated helpful discoloration for all receptor sub-types all through the “tubular system”. Our research team also looked at the location of SomatostatinR in the kidney. SomatostatinR2 expression was found mostly in “distal tubules” as well as gathering ducts in mice, which matched mRNA expression. We observed contradictory evidence for immunostainings as well as mRNA expression in people. However, comparing human research is challenging since most concentrate on just limited parts of the kidneys or various antibodies were utilised, often with differing antigen specificity for Somatostatin receptors. It's crucial to understand that Somatostatin receptor subtypes are represented in numerous parts of the nephron for Somatostatin analogue treatment, which will be covered later. As a result, additional study into SomatostatinRs' renal localisation is needed.

Consequence of Somatostatin pathway initiation in renal physiology:

Somatostatin binding to Somatostatin receptors may trigger pathways that influence renal cell function as well as proliferation, as previously discussed. Somatostatin presumably influences renal cell activity and proliferation in an autocrine/paracrine way since renal cells both produce Somatostatin and exhibit Somatostatin receptors. “This notion is reinforced by the fact that, whereas all Somatostatin receptors exhibit nanomolar affinity for physiologically active Somatostatin (Somatostatin -14 and Somatostatin -28), systemic fasting plasma Somatostatin levels are 100–1000 times lower, ranging between 0.008 and 0.02 nM, or 14–32.5 pg/mL”. These extremely low levels are thought to be too low to trigger Somatostatin receptors in the kidney. Given that Somatostatin is partially removed by the kidney, processed Somatostatin might conceivably reach larger amounts in (pre)urine, thereby modulating downstream tubular functioning. The production of aldosterone as well as renin is inhibited when Somatostatin receptors are activated. Somatostatin is thought to be involved in renal water management and may suppress renal cell growth, according to many studies. Moreover, Somatostatin produces glomerular vasoconstriction, which causes a decrease in renal blood flow and, as a consequence, a drop-in glomerular filtration rate (GFR). Somatostatin 's capacity to decrease renal cAMP

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

synthesis is likely responsible for all, or at least a portion, of these physiological activities. Surprisingly, high level of cAMP constitute one of the key negative aspects in the pathogenesis of ADPKD. Somatostatin and similar agonists have the ability to have a therapeutic impact in Autosomal Dominant Polycystic Kidney Disease in theory.

Somatostatin Analogues:

Several analogues with differing sensitivities for the Somatostatin receptors subtypes occur due to changes in ring chemistry, size, as well as location of bridging units. Octreotide, lanreotide, and pasireotide are the most common and clinically utilised SST analogues. These medications have a lot of clinical experience since they've been used for a long time to treat neuroendocrine illnesses including acromegaly by reducing growth hormone production, as well as neuroendocrine tumours by decreasing serotonin release. For each purpose, different Somatostatin equivalents, administration routes, and dose regimens are employed.

Table 1: SST analogues and their characteristics

SST analogue	Manufacturer	Receptor affinity [38]	Registered indications	Administration route	Half-life	Dosing regimen
Octreotide (SMS 201-995, Sandostatin)	Novartis Pharmaceuticals	SSTR2 > SSTR3, -5	Acromegaly Gastro-entero-pancreatic endocrine tumours Advanced neuroendocrine tumours TSH-secreting pituitary adenomas Prevention of complications after pancreatic surgery Acute oesophageal variceal bleeding	IR Subcutaneous Intravenous LAR Intramuscular	IR Subcutaneous 100 min LAR steady state for 3–4 weeks	IR Subcutaneous 2–3× per day Intravenous continuous LAR 1× per 4 weeks
Lanreotide (BIM 23014, Somatuline)	Ipsen Ltd.	SSTR2 > SSTR3, -5	Acromegaly Gastro-entero-pancreatic-neuroendocrine tumours Thyrotropic adenomas	ATG Subcutaneous SR Intramuscular	ATG 23–30 days SR 5 days	ATG 1× per 4 weeks SR 1× per 7–14 days
Pasireotide (SOM-230, Signifor)	Novartis Pharmaceuticals	SSTR1, -2, -3, -5	Acromegaly Cushing's disease	IR Subcutaneous LAR Intramuscular	IR 12 h LAR 16 days	IR 2× per day LAR 1× per 4 weeks

IR, immediate-release; LAR, long-acting release; ATG, autogel; SR, slow-release. The information in this table is derived from https://www.medicines.org.uk/emc/. Year of last update 2016 for octreotide and lanreotide; 2017 for pasireotide; Year of access 2018.

Diagnosis of ADPKD

Those who have a family history of ADPKD (i.e., whose parents, siblings, or children have ADPKD) should be screened for the disease. It is especially important to interview relatives from three generations in-depth about their family history of the illness.[13] "While criteria are lacking, when bilateral renal cysts are present and two of the following criteria are also met, the condition can be presumed to be renal cystic carcinoma: bilateral renal enlargement, the presence of more than two hepatic cysts, the presence of a cerebral aneurysm, or a solitary cyst in the arachnoid, pineal gland, pancreas, or spleen. People aged 15 to 39 should have three or more cysts on one or both kidneys to diagnose renal cysts". To prevent problems, everyone in this age group should have two cysts in each kidney.[14] It is possible that genetic testing may lead to the discovery of a particular PKD1 or PKD2 mutation. There are a limited number of applications where this kind of testing is used, but it should be.

Treatment:

High blood pressure is a frequent and early symptom of illness in patients with advanced kidney disease (ADPKD), and when left uncontrolled, Because ADPKD leads to more cardiovascular complications than normotensive ADPKD, the development of end-stage renal disease and cardiovascular repercussions is much quicker in those with ADPKD. Despite the well-established link between high blood pressure and decreased renal and patient outcomes in ADPKD.[15] The RAAS blockers, which traditionally have been viewed as the most effective in treating hypertension associated with ADPKD, remain an enigma.

Transplant:

The normal age at transplant for Autosomal Dominant Polycystic Kidney Disease patients is 51.2 8.6, with no statistically significant differences in "post-transplant hypertension, proteinuria, erythrocytosis, acute rejection episodes, graft function, and, most importantly", the prevalence of acute rejection episodes compared to other renal transplant patients. Patients with ADPKD, on the other hand, had a substantially higher risk of acquiring diabetes mellitus after transplantation as compared to non-ADPKD patients, according to the study. Simultaneous nephrectomy may also be done at the time of transplantation, and recent research shown that it results in low morbidity while eliminating the hazards of interval dialysis.[16] This combined approach,

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

however, is not without hazards, which include one incidence of wound dehiscence and one case of adrenal insufficiency identified throughout the study.

III. NOVEL THERAPIES

mTOR inhibitors

Renal tubular epithelial cell proliferation is increased in ADPKD patients and animal models, which has been demonstrated to be associated with activation of the mTOR pathway in both people and animal models of the disease.[18] Therefore, new treatments for ADPKD include the use of mTOR pathway inhibitors, such as rapamycin and everolimus, which have been demonstrated in animal models to decrease cyst development and maintain renal function. Rapamycin and everolimus are examples of such medicines.

A randomised, single-blind study in 2009 was carried out with 8 ADPKD patients who received "1 mg per day of rapamycin in their mouth for six months in addition to the Angiotensin receptor blocker telmisartan", one of the most current data supporting the use of rapamycin in humans. In addition, eight more ADPKD patients were just given telmisartan as the control group.[19-20] Prior to the start of the research, all of the patients included had creatinines less than 2.0 mg/dL and negative urine cultures, indicating that they were in good health. Kidney function was stable in three patients who got the only treatment, worsened in three others, and improved in two more patients who also received the treatment. There were two cases of urinary tract infection in the treatment group and two cases of monilial pharyngitis in the control group, compared to just two infections in the treatment group. Notably, kidney capacity in the regulator cluster increased significantly from 2668 mL at the start of the research to 3591 mL after 6 months of treatment, whereas the treatment group had a considerably lower volume increase.[21] This was despite both groups receiving the same amount of medication. As a result, the authors believe that rapamycin, when used in conjunction with an ARB, may be helpful in the treatment of ADPKD.

Symptomatic Treatment

In addition to rigorous blood pressure management, the main emphasis of therapy for ADPKD is prevention and supportive measures.[22] This includes pain management, medications for urinary tract infections, adequate hydration, and avoiding caffeine and smoking. Because not all cysts interact with the "urinary region, patients with parenchymal and cyst involvement may develop a urinary tract infection".

The considerable "stomach, back, and flank discomfort associated with ADPKD is often severe enough" to prevent patients from doing their normal daily activities. Depending on the severity of the mass effect caused by the huge development of the kidneys, or the severity of individual cyst rupture, this pain is often felt in the lower back or abdomen. It is not known what causes this pain.[23-24] Pain treatment may be challenging in these individuals since conventional methods, like the practice of non-steroidal anti-inflammatory drugs (NSAIDs), should be avoided because of their impact on the kidneys.[25] Naloxone should only be used for acute pain episodes in order to reduce the risk of developing dependency on these medications. Despite these efforts, individuals with ADPKD have pain that is controllable by oral analgesics in a range of 50–70 percent of the population. Therefore, when conservative treatments are ineffective, surgical alternatives are accessible to the patient. The most common of them is "cyst decortication, which is now done laparoscopically and has been shown in a study of 29 ADPKD patients to result in a higher than 50% reduction in pain in 73 percent of patients at 12 months, 52 percent at 24 months, and 81 percent at 36 months". At the same time, separate research of 15 Autosomal Dominant Polycystic Kidney Disease patients cured with laparoscopic decortication found that pain reduced an average of 62 percent in 73 percent of cases after an average follow-up of 2.2 years (range 0.5–5). Further research is required to establish the advantages of decortication in the context of long-term pain reduction. The treatment is not without risks, however, and there have been reports of postoperative "bleeding, ileus, increasing hypertension, arrhythmia, pneumonia, and even death" as a result of the surgery.[26] Renal artery embolization is a promising new treatment option for the symptoms related with the mass effect of the kidneys. It is now being tested in clinical trials. In this technique, the major renal artery is embolized; however, selective embolization has been tried in the past. It is usually done exclusively on "dialysis-dependent patients" since it completely destroys any residual renal function, effectively lowering GFR to 0 in the process. "This is particularly essential to consider in patients with end-stage renal disease who still have some residual renal function, since renal artery embolization will remove this remaining function, as well as any possible advantages to quality of life that it may provide".[27] But a number of studies have shown that the technique may successfully cure hematuria and shrink kidney size while causing only minor side effects such as transient flank discomfort, fever, nausea and vomiting. The operation is performed under general anaesthesia.

Vasopressin Receptor Antagonists

In addition to increased fluid production from renal tubular epithelial cells, cyst development and expansion are believed to be caused in part by increased cell proliferation mediated by the mTOR pathway.[28] There are a variety of signalling cascades that are involved in the secretion of fluid, including those that are involved in the production of cAMP. Therefore, medications that interfere with this system, such as vasopressin receptor antagonists, are being investigated as possible therapeutic options for patients with Parkinson's disease. Vasopressin receptor antagonists

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

work by interfering with the binding of vasopressin to V2 receptors, which are usually found in kidney collecting ducts, which are the main site of cyst formation in ARPKD and potentially in ADPKD, among other places. Vasopresensin stimulates adenylyl cyclase when it binds to V2 receptors, resulting in the generation of cAMP, which promotes cyst formation by boosting fluid secretion and proliferative activity. It was hypothesised that by inhibiting this route, disease development might be disturbed and possibly prevented if the illness was treated early in the disease course. In a rapid move of cystic models of cpk mice, OPC-31260, a V2 antagonist, inhibited cystic growth and azotemia and reduced the incidence of the cystic illness.[29] Another investigation has shown that tolvaptan may be helpful for the treatment of severe hypervolemic and euvolemic hyponatremias even though it is much higher in the animal model of PKD. The findings of the Phase 2 component of Tolvaptan are safe and well-tolerated by ADPKD persons. One of the program's most significant studies, a large placebo-controlled, double-blind study, is currently underway. It is enrolling patients aged 18 to 50 who have ADPKD, but have preserved renal function and are experiencing relatively rapid progression of the disease, as “defined by total kidney volumes greater than 750 mL”.[30] The findings of the research should provide light on the effectiveness of tolvaptan in terms of delaying disease development.

IV. OCTREOTIDE

Octreotide has therapeutic promise since it inhibits the synthesis of cAMP in the body. It was by chance that a people having Autosomal Dominant Polycystic Kidney Disease including a pituitary adenoma was discovered to be stabilising the size of their renal cysts while being treated with somatostatin that the drug was initially considered as a possible therapeutic option for these individuals. SST has now been exposed in PCK rats to lesser blood cAMP stages in animal models as well as to reduce kidney weights, kyst volumes as well as kidney fibrosis, but no effect has been shown on kidney function in these rats.[31] Octreotide in humans have been shown to be well-tolerated and to reduce significantly renal volume growth in a six-month, randomised, crossover, placebo-controlled trial, in particular by slowing down formation of smaller size cysts and being well tolerated. Again, octreotide had no effect on the GFR compared to controls. There are many examples. The drug's long-term advantages are yet unclear, and studies are now being conducted to better understand somatostatin's function in therapy.

Additional Agents

There are a number of other experimental drugs in the treatment of ADPKD that are still under study. These comprise “roscovitine, triptolide, pioglitazone, and etanercept”, the functions of which can be clearer as time progresses.[32] As additional information gets known regarding the numerous experimental medicines currently being evaluated in individuals with Parkinson's disease (Table 1), new treatment suggestions that may be beneficial to these patients may become accessible. In the interim, patients should be encouraged to adhere to existing management recommendations, according to the guidelines.

Baseline Characteristics

Sex-Age matched stable monitors and function-matched IgA nephropathy (IgAN). The baseline characteristics of the samples of ADPKD patients and similarly aged, adult, adult, and normal kidney function patients (ADPKD, IgA Nephropathy) are shown in Table 1. In the categories with significantly lower kidney capacity, renal failure and patients were shown in the two comparison groups[33]. Secondly, the greater frequency of significant decreases in 24-hour sodium excretion was shown in patients with Autosomal Dominant Polycystic Kidney Disease as well as with IgA nephropathy, further supporting their suggestion to follow moderate sodium intake recommendations.

With the data provided as median (with nonparametric methods used), total active is characterised as the amount of 5α-reductase and cortisol excretion, calculated as THF + aTHF, 11β; nonparametric values for discrepancies between study pools were checked with the Shapiro-Wilk 12 test for the sum of THF and TCHF (5α-THF). The level of the polysaturic acid decreases (reduces) while the body is deprived of water[34]; AutoT does too, although the rate is different, whereas for those with Autosomal Dominant Polycystic Kidney Disease, it varies; activity in the level of the immunoglobulin A; an interquartile range occurs.

In kidney and patients that use an antagonist with the V2 receptor



V. CONCLUSION

Among the most frequent hereditary diseases is ADPKD. Appropriate therapy alternatives for ADPKD are desperately needed, with an occurrence ten times that of sickle cell disease as well as Fifteen times that of cystic fibrosis. Latest, focused therapies have been developed to disrupt cell signalling pathways liable for

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

the irregular dedifferentiation, apoptosis, cell proliferation, as well as fluid secretion seen in Autosomal dominant polycystic kidney disease and ARPKD as a consequence of latest developments in our comprehension of the molecular and genetic pathogenesis of both diseases. Despite the absence of conclusive solutions, several of such novel therapeutic medicines show potential in limiting or regulating cyst formation, offering much-needed relief in this seemingly unending ailment.

REFERENCES

[1] Torres VE et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. *N. Engl. J. Med*. 377, 1930–1942 (2017).
[2] Chebib FT et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. *J. Am. Soc. Nephrol*. 29, 2458–2470 (2018).
[3] Boertien WE, Meijer E, de Jong PE, Ter Horst GJ, Renken RJ, van der Jagt EJ, et al. Short- term effects of tolvaptan in individuals with autosomal dominant polycystic kidney dis- ease at various levels of kidney function. 2015;65(6):833–41.
[4] Torres VE, Chapman AB, Devuyst O, Gan- sevoort RT, Perrone RD, Koch G, et al. RE- PRISE Trial Investigators: tolvaptan in later- stage autosomal dominant polycystic kidney disease. 2017;377(20):1930–42.
[5] Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, et al. TEMPO 3:4 Investigators: plasma copeptin levels predict disease progression and tolvap- tan efficacy in autosomal dominant polycystic kidney disease. 2019;96(1):159–69.
[6] Knepper MA, Kwon TH, Nielsen S. Molecular physiology of water balance. 2015;372(14):1349–58.
[7] Chebib FT & Torres VE Autosomal dominant polycystic kidney disease: core curriculum 2016. *Am. J. Kidney Dis*. 67, 792–810 (2016).
[8] Nowak KL et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. *J. Am. Soc. Nephrol*. 29, 571–578 (2018).
[9] Koshimizu TA, Nakamura K, Egashira N, Hi- royama M, Nonoguchi H, Tanoue A. Vaso- pressin V1a and V1b receptors: from mole- cules to physiological systems. 2012;92(4):1813–64.
[10] Rotondo F, Butz H, Syro LV, Yousef GM, Di Ieva A, Restrepo LM, et al. Arginine vasopres- sin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. 2016;19(4):345–55.
[11] Nakamura K, Velho G, Bouby N. Vasopressin and metabolic disorders: translation from ex- perimental models to clinical use. 2017;282(4):298–309.
[12] Dell KM et al. Kidney disease progression in autosomal recessive polycystic kidney disease.*J. Pediatr*. 171, 196–201 (2016).
[13] Liu L, Li K, Fu X, Chung C & Zhang KA Forward look at noninvasive prenatal testing. *Trends Mol. Med*. 22, 958–968 (2016).
[14] Marlais M et al. Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. *Arch. Dis. Child* 101, 1142–1147 (2016).
[15] Gansevoort RT et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. *Nephrol. Dial Transpl*. 31, 337–348 (2016).
[16] Irazabal MV et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. *J. Am. Soc. Nephrol*. 26, 160–172 (2015).
[17] Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, et al. Cardiovas- cular events and mortality in patients with ad- renal incidentalomas that are either non-se- creting or associated with intermediate phe- notype or subclinical Cushing's syndrome: a 15-year retrospective study. 2014;2(5):396–405.
[18] Park J, De Luca A, Dutton H, Malcolm JC, Doyle MA. Cardiovascular outcomes in autonomous cortisol secretion and nonfunc- tioning adrenal adenoma: a systematic re- view. 2019;3(5):996–1008.
[19] De Rechter S et al. Clinicians' attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease. *PLOS ONE* 12, e0185779 (2017).
[20] Massella L et al. Prevalence of hypertension in children with early-stage ADPKD. Clin. *J. Am. Soc. Nephrol*. 13, 874–883 (2018).
[21] Tan AY et al. Autosomal dominant polycystic kidney disease caused by somatic and germlinemosaicism. *Clin. Genet*. 87, 373–377 (2015).
[22] de Jong WHA, Buitenwerf E, Pranger AT, Riphagen IJ, Wolffenbuttel BHR, Kerstens MN, et al. Determination of reference inter- vals for urinary steroid profiling using a new- ly validated GC-MS/MS method. 2017;56(1):103–12.
[23] Lanktree MB et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. *J. Am. Soc. Nephrol*. 29, 2593–2600 (2018).
[24] WerumeusBuning J, van Faassen M, Brum- melman P, Dullaart RP, van den Berg G, van der Klauw MM, et al. Effects of hydrocorti- sone on the regulation of blood pressure: re- sults from an RCT. 2016;101(10):3691–9.
[25] Castelli M et al. Regulation of the microtubular cytoskeleton by Polycystin-1 favors focal adhesions turnover to modulate cell adhesion and migration. *BMC Cell Biol*. 16, 15 (2015).
[26] Kunimoto K et al. Disruption of core planar cell polarity signaling regulates renal tubule morphogenesis but is not cystogenic. *Curr. Biol*. 27, 3120–3131 (2017).

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

[27] Cuzzola A, Mazzini F, Petri A. A comprehen- sive study for the validation of a LC-MS/MS method for the determination of free and total forms of urinary cortisol and its metabolites. 2014;94:203–9.
[28] Eisenberger T et al. An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease. *PLOS ONE* 10, e0116680 (2015).
[29] Mallawaarachchi AC et al. Whole-genome sequencing overcomes pseudogene homology to diagnose autosomal dominant polycystic kidney disease. *Eur. J. Hum. Genet*. 24, 1584–1590 (2016).
[30] Rosmalen JG, Kema IP, Wüst S, van der Ley C, Visser ST, Snieder H, et al. 24 H urinary free cortisol in large-scale epidemiological studies: short-term and long-term stability and sources of variability. 2014;47:10–6.
[31] Kleeberger C, Shore D, Gunter E, Sandler DP, Weinberg CR. The effects of long-term stor- age on commonly measured serum analyte levels. 2018;29(3):448–52.
[32] Heida JE, Boesten LS, Ettema EM, Muller Ko- bold AC, Franssen CF, Gansevoort RT, et al. Comparison of ex vivo stability of copeptin and vasopressin. 2017; 55(7):984–92.
[33] Katz DA, Locke C, Liu W, Zhang J, Achari R, Wesnes KA, et al. Single-dose interaction study of the arginine vasopressin type 1B re- ceptor antagonist ABT-436 and alcohol in moderate alcohol drinkers. 2016;40(4):838–45.
[34] Kacheva S, Kolk K, Morgenthaler NG, Bra- bant G, Karges W. Gender-specific co-activa- tion of arginine vasopressin and the hypotha- lamic-pituitary-adrenal axis during stress. 2015;82(4):570–6.
[35] Cabezas OR et al. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2. *J. Am. Soc. Nephrol*. 28, 2529–2539 (2017).
[36] Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, et al. Autosomal domi- nant polycystic kidney disease is associated with central and nephrogenic defects in osmo- regulation. 2012;82(10):1121–9. Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. 2012;7(6):906–13.
[37] Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE. Vasopressin and disruption of cal- ciumsignalling in polycystic kidney disease. 2015;11(8):451–64.
[38] Zittema D, Casteleijn NF, Bakker SJ, Boesten LS, Duit AA, Franssen CF, et al. Urine con- centrating capacity, vasopressin and copeptin in ADPKD and IgA nephropathy patients with renal impairment. 2017; 12(1):e0169263.
[39] Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, et al. Copeptin, a surro- gate marker of vasopressin, is associated with disease severity in autosomal dominant poly- cystic kidney disease. 2011;6(2):361–8.
[40] Bergmann C Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. *Front. Pediatr*. 10.3389/fped.2017.00221 (2018).
[41] Cardoso EM, Arregger AL, Budd D, Zucchini AE, Contreras LN. Dynamics of salivary cor- tisol in chronic kidney disease patients at stag- es 1 through 4. 2016;85(2): 313–9.
[42] Lorthioir A et al. Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. *Kidney Int*. 87, 465–472 (2015).
[43] Hunter RW, Bailey MA. Glucocorticoids and 11beta-hydroxysteroid dehydrogenases: mechanisms for hypertension. 2015;21:105–14.
[44] Lu H et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. *Nat. Genet*. 49, 1025–1034 (2017).
[45] Sagmeister MS, Taylor AE, Fenton A, Wall NA, Chanouzas D, Nightingale PG, et al. Glu- cocorticoid activation by 11beta-hydroxys- teroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: a cross-sectional study. 2019;90(1):241–9.
[46] Chen L et al. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.*J. Clin. Invest*. 125, 2399–2412 (2015).
[47] Gant CM, Minovic I, Binnenmars H, de Vries L, Kema I, van Beek A, et al. Lower renal func- tion is associated with derangement of 11-β hydroxysteroid dehydrogenase in type 2 dia- betes. 2018;2(7):609–20.
[48] Huang JL et al. Vascular endothelial growth factor C for polycystic kidney diseases. *J. Am. Soc. Nephrol*. 27, 69–77 (2016).
[49] Menezes LF, Lin CC, Zhou F &Germino GG Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. *EBioMedicine* 5, 183–192 (2016).
[50] Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A. Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hor- mone. 1995;35(8):776–9.
[51] Ghazi L, Dudenbostel T, Hachem ME, Sid- diqui M, Lin CP, Oparil S, et al. 11-beta dehy- drogenase type 2 activity is not reduced in treatment resistant hypertension. 2017;30(5):518–23.
[52] Rodriguez D et al. Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in han: SPRD rats with polycystic kidney disease. *Kidney Blood Press Res*. 40, 638–647 (2015).
[53] Hillebrand JJ, Heijboer AC, Endert E. Effects of repeated freeze-thaw cycles on endocrine parameters in plasma and serum. 2017;54(2):289–92
[54] Willey CJ et al. Prevalence of autosomal dominant polycystic kidney disease in the European

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Union. *Nephrol. Dial. Transplant*. 32, 1356–1363 (2017).
[55] Bergmann C ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. *Pediatr. Nephrol.* 30, 15–30 (2015).
[56] Willey CJ et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. *Nephrol. Dial. Transplant*. 32, 1356–1363 (2017).
[57] Cornec-Le Gall E, Torres VE & Harris PC Genetic complexity of autosomal dominant polycystic kidney and liver diseases. *J. Am. Soc. Nephrol*. 29, 13–23 (2018).
[58] Riwanto M et al. Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. *PLOS ONE* 11, e0146654 (2016).
[59] Alzarka B, Morizono H, Bollman JW, Kim D &Guay-Woodford LM Design and Implementation of the Hepatorenal Fibrocystic Disease Core Center Clinical Database: a centralized resource for characterizing autosomal recessive polycystic kidney disease and other hepatorenal fibrocystic diseases. *Front. Pediatr*. 5, 80 (2017).
[60] Gimpel C et al. Perinatal diagnosis, management, and follow-up of cystic renal diseases: a clinical practice recommendation with systematic literature reviews. *JAMA Pediatr*. 172, 74–86 (2018).
[61] Porath B et al. Mutations in GANAB, encoding the glucosidaseIIa subunit, cause autosomal-dominant polycystic kidney and liver disease. *Am. J. Hum. Genet*. 98, 1193–1207 (2016).
[62] Besse W et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. *J. Clin. Invest*. 127, 3558 (2017).
[63] Cornec-Le Gall E et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. *Am. J. Hum. Genet*. 102, 832–844 (2018).
[64] Chapman AB et al. Autosomal dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) *Controversies Conference. Kidney Int*. 88, 17–27 (2015).
[65] Bolar NA et al. Heterozygous loss-of-function SEC61A1 mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. *Am. J. Hum. Genet*. 99, 174–187 (2016).
[66] Xu Y et al. The polycystin-1, lipoxygenase, and a-toxin domain regulates polycystin-1 trafficking. *J. Am. Soc. Nephrol*. 27, 1159–1173 (2016).
[67] Shen PS et al. The structure of the polycystic kidney disease channel PKD2 in lipid nanodiscs. *Cell* 167, 763–773 (2016).
[68] Grieben M et al. Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2). *Nat. Struct. Mol. Biol*. 24, 114–122 (2017).
[69] Leonhard WN et al. Scattered deletion of PKD1 in kidneys causes a cystic snowball effect and recapitulates polycystic kidney disease. *J. Am. Soc. Nephrol*. 26, 1322–1333 (2015).
[70] Heyer CM et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. *J. Am. Soc. Nephrol*. 27, 2872–2884 (2016).
[71] Cornec-Le Gall E et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. *J. Am. Soc. Nephrol*. 27, 942–951 (2016).
[72] Chebib FT et al. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. *Nephrol. Dial. Transplant*. 31, 952–960 (2016).
[73] Audrezet M-P et al. Comprehensive PKD1 and PKD mutation analysis in prenatal autosomal dominant polycystic kidney disease. *J. Am. Soc. Nephrol*. 27, 722–729 (2016).
[74] Iliuta IA et al. Polycystic kidney disease without an apparent family history. *J. Am. Soc. Nephrol*. 28, 2768–2776 (2017).
[75] Chiaravalli M et al. 2-deoxy-d-glucose ameliorates PKD progression. *J. Am. Soc. Nephrol*. 27, 1958–1969 (2016).

This work is under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.